Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
PTC THERAPEUTICS, INC. (PTCT)
|
Add to portfolio |
|
|
|
| Price: |
$42.58
| | Metrics |
| OS: |
75.3
|
M
| |
|
|
| Market cap: |
$3.21
|
B
| |
|
|
|
Net debt:
|
$235
|
M
| |
|
|
|
EV:
|
$3.44
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($294)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 538.6 | 380.8 | 307.0 | 264.7 | 194.4 | 82.7 | 36.8 | 25.2 |
| Revenue growth | 41.4% | 24.0% | 16.0% | 36.2% | 135.0% | 124.9% | 45.6% | -27.2% |
| Cost of goods sold | 32.3 | 18.9 | 12.1 | 12.7 | 4.6 | 0.0 | 0.0 | 0.0 |
| Gross profit | 506.3 | 361.8 | 294.8 | 252.1 | 189.8 | 82.7 | 36.8 | 25.2 |
| Gross margin | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 285.8 | 245.2 | 202.5 | 153.5 | 121.3 | 97.1 | | |
| Research and development | 540.7 | 477.6 | 257.5 | 172.0 | 117.5 | 117.6 | 121.8 | 79.8 |
| General and administrative | | | | | | | 82.1 | 44.8 |
| EBITA | -320.2 | -371.6 | -137.4 | -73.5 | -48.9 | -132.1 | -167.1 | -99.4 |
| EBITA margin | -59.4% | -97.6% | -44.8% | -27.8% | -25.2% | -159.7% | -454.6% | -393.8% |
| Amortization of intangibles | 54.8 | 36.9 | 55.4 | 22.9 | 15.4 | | | |
| EBIT | -374.9 | -408.5 | -192.8 | -96.3 | -64.3 | -132.1 | -167.1 | -99.4 |
| EBIT margin | -69.6% | -107.3% | -62.8% | -36.4% | -33.1% | -159.7% | -454.6% | -393.8% |
| Pre-tax income | -518.3 | -402.9 | -239.9 | -128.1 | -77.7 | -141.5 | -170.0 | -98.4 |
| Income taxes | 5.6 | 35.2 | 11.7 | 0.0 | 1.3 | 0.6 | 0.5 | 4.7 |
| Tax rate | | | | 0.0% | | | | |
| Net income | -523.9 | -438.2 | -251.6 | -128.1 | -79.0 | -142.1 | -170.4 | -93.8 |
| Net margin | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% |
| |
| Diluted EPS | ($7.43) | ($6.64) | ($4.27) | ($2.75) | ($2.02) | ($4.17) | ($5.07) | ($2.97) |
| Shares outstanding (diluted) | 70.5 | 66.0 | 58.9 | 46.6 | 39.2 | 34.0 | 33.6 | 31.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|